Cardiol Therapeutics Inc. (CRDL), a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, faces a make-or-break moment this month - assuming it sticks to its announced timeline.
The company's lead drug candidate is CardiolRx (cannabidiol) oral solution, which works by reducing inflammation through several pathways. This includes blocking the NLRP3 inflammasome, which is known to drive inflammation and scarring in conditions like pericarditis, myocarditis, and heart failure.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com